Albireo Pharma’s (ALBO) “Buy” Rating Reiterated at Wedbush

Albireo Pharma (NASDAQ:ALBOGet Rating)‘s stock had its “buy” rating restated by Wedbush in a research note issued to investors on Tuesday, TipRanks reports. They presently have a $72.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 220.28% from the stock’s previous close.

A number of other analysts also recently weighed in on the stock. Robert W. Baird cut their price target on shares of Albireo Pharma from $72.00 to $66.00 in a research report on Tuesday. began coverage on shares of Albireo Pharma in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Albireo Pharma has an average rating of “Buy” and an average price target of $62.00.

Shares of ALBO stock traded down $5.56 during trading hours on Tuesday, reaching $22.48. The company had a trading volume of 32,539 shares, compared to its average volume of 213,085. Albireo Pharma has a 1-year low of $20.30 and a 1-year high of $37.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The firm has a market cap of $435.21 million, a price-to-earnings ratio of -12.09 and a beta of 0.95. The company has a 50 day moving average of $31.95 and a 200 day moving average of $28.71.

Albireo Pharma (NASDAQ:ALBOGet Rating) last released its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.17). Albireo Pharma had a negative net margin of 83.86% and a negative return on equity of 74.80%. During the same period in the prior year, the company posted ($2.29) earnings per share. As a group, sell-side analysts forecast that Albireo Pharma will post -7.11 EPS for the current fiscal year.

In related news, CEO Ronald Harold Wilfred Cooper sold 907 shares of the business’s stock in a transaction that occurred on Friday, April 22nd. The stock was sold at an average price of $33.11, for a total value of $30,030.77. Following the completion of the transaction, the chief executive officer now directly owns 56,082 shares in the company, valued at approximately $1,856,875.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 1,872 shares of company stock worth $61,139 in the last quarter. 5.80% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Decheng Capital Management III Cayman LLC bought a new stake in shares of Albireo Pharma in the first quarter valued at about $15,462,000. Nicholas Investment Partners LP acquired a new stake in Albireo Pharma in the 1st quarter valued at approximately $13,102,000. Privium Fund Management UK Ltd bought a new stake in Albireo Pharma in the 4th quarter valued at approximately $8,959,000. Chicago Capital LLC boosted its position in Albireo Pharma by 19.1% during the 1st quarter. Chicago Capital LLC now owns 1,011,744 shares of the biopharmaceutical company’s stock worth $30,180,000 after acquiring an additional 162,505 shares during the last quarter. Finally, MAI Capital Management grew its stake in shares of Albireo Pharma by 1,142.7% during the 4th quarter. MAI Capital Management now owns 139,551 shares of the biopharmaceutical company’s stock worth $3,250,000 after acquiring an additional 128,321 shares in the last quarter. Hedge funds and other institutional investors own 82.99% of the company’s stock.

Albireo Pharma Company Profile (Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.

Featured Stories

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.